This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/wikipedia/
n30http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/kegg-compound/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/bindingdb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/pubchem-compound/
n21http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/national-drug-code-directory/
owlhttp://www.w3.org/2002/07/owl#
n29http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n8http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00899/identifier/chemspider/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00899
rdf:type
n3:Drug
n3:description
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.
n3:dosage
n14:271B5B63-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1-20 minutes
n3:indication
For use during the induction and maintenance of general anesthesia.
n3:manufacturer
n7:271B5B5F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n20:DB00899 n21:DB00899
dcterms:title
Remifentanil
adms:identifier
n12:Remifentanil n17:46504538 n18:PA451232 n22:60815 n23:C08021 n24:67457-198-03 n25:DB00899 n26:50012491 n27:54803
n3:mechanismOfAction
Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
n3:packager
n7:271B5B5D-363D-11E5-9242-09173F13E4C5 n7:271B5B5E-363D-11E5-9242-09173F13E4C5 n7:271B5B5C-363D-11E5-9242-09173F13E4C5
n3:patent
n13:5019583 n13:5866591
n3:routeOfElimination
Remifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.
n3:synonym
REMIFENTANIL Remifentanyl
n3:volumeOfDistribution
* 350 mL/kg * 452 ± 144 mL/kg [neonates] * 223 ± 30.6 mL/kg [adolescents]
n9:hasAHFSCode
n15:28-08-08
n3:proteinBinding
70% (bound to plasma proteins)
n3:synthesisReference
Jacob Mathew, J. Killgore, "New methods for the synthesis of alfentanil, sufentanil, and remifentanil." U.S. Patent US20060149071, issued July 06, 2006.
n29:hasConcept
n30:M0194769
foaf:page
n6:remifentanil.html n8:ultiva.htm
n3:IUPAC-Name
n4:271B5B68-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5B6E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5B6D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5B6A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5B6B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5B6C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5B66-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5B67-363D-11E5-9242-09173F13E4C5 n4:271B5B64-363D-11E5-9242-09173F13E4C5 n4:271B5B7D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5B65-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N01AH06
n3:H-Bond-Acceptor-Count
n4:271B5B74-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5B75-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5B6F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5B70-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5B72-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5B71-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5B73-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
132875-61-7
n3:category
n3:clearance
* 40 mL/min/kg [young, healthy adults]
n3:containedIn
n28:271B5B62-363D-11E5-9242-09173F13E4C5 n28:271B5B60-363D-11E5-9242-09173F13E4C5 n28:271B5B61-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5B79-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5B7B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5B7C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5B78-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5B77-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5B7A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5B69-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5B76-363D-11E5-9242-09173F13E4C5